NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









IntraGel Therapeutics

IntraGel Therapeutics

Private
NazarethHealthcare & Life Scienceshttps://intra-gel.com/

Last Round

Seed

Aug 3, 2023

Total Funding Raised

$450,000

Company Overview

IntraGel Therapeutics is a biotechnology company that develops a proprietary gel-based drug delivery platform, SRGel, for the localized and sustained release of anti-cancer medications in solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug deliveryoncologysolid tumorssustained releaseinjectable hydrogelbiotechchemotherapybiodegradable polymerclinical trialsdrug delivery platformintratumoral injectionlocal drug deliverynanomedicinecancer therapydrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IntraGel Therapeutics Comparables

Compare IntraGel Therapeutics with similar companies based on industry and business-model similarity.

IntraGel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Johnson & Johnson
70%
Everfront Biotech Inc.
66%
InhaTarget Therapeutics
63%

IntraGel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 3, 2023
Pre SeedMay 1, 2023
AcceleratorJul 21, 2022
SeedAug 1, 2021

Key People

Founding team and executive leadership

Peter Siman

Chief Executive Officer

Executive Team

IntraGel Therapeutics Investors

Notable investors and investment history

IntraGel Therapeutics investors
InvestorRounds
Israel Innovation AuthorityPre Seed
Next Generation Technology (NGT3VC)Seed
MassChallenge IsraelAccelerator
NGT HealthCare IIPre Seed

IntraGel Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IntraGel Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IntraGel Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNazareth
Employee Range5
Year Founded2020
Last FundingAug 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.